“We are very pleased to share intriguing new non-clinical data that suggest there is immune-suppressive cross-talk between IL-27 and PD-L1 expression within the tumor microenvironment,” said
SITC Poster Presentations:
Title: IL-27 expressed in the tumor microenvironment is correlated with PD-L1 levels and can induce PD-L1 expression on immune and tumor cells
Poster/Abstract: 1082
Session Type/Title: Immune-stimulants and immune-modulators
Session Date and Time:
Summary of key data:
- Primary tumor samples from several cancers including lung, liver, renal, gastric, and head and neck, have IL-27+ tumor associated macrophages (TAMs).
- IL-27-expressing TAMs are localized within the vicinity of PD-L1+ tumor cells in lung and liver cancers, with the highest IL-27+ density being associated with the highest PD-L1 expression.
- IL-27 can regulate PD-L1 expression in immune cells and tumor cell lines.
Title: SRF114, an afucosylated anti-CCR8 antibody, depletes intratumoral Treg cells and reduces tumor growth
Abstract/Poster: 1388
Session Type/Title: Novel Single-Agent Immunotherapies
Session Date and Time:
Summary of key data:
- CCR8 expression is highest on intratumoral regulatory T (Treg) cells compared to peripheral Tregs and other immune cells.
- SRF114 treatment results in dose-dependent activation of immune cells, including natural killer (NK) cells and monocytes.
- In dissociated tumor cultures, SRF114 selectively depletes Treg cells and has limited impact on effector T cells; in a mouse model, SRF114 treatment significantly reduces tumor growth and depletes intratumoral Treg cells, with minimal impact on peripheral Tregs.
The posters will be available on Surface Oncology’s website on
About SRF388
SRF388 is a fully human anti-IL-27 antibody designed to inhibit the activity of this immunosuppressive cytokine.
About SRF114
SRF114 is a fully human, afucosylated anti-CCR8 antibody designed to preferentially deplete CCR8+ Treg cells within the tumor microenvironment. In pre-clinical studies,
About
Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment. Its pipeline includes two wholly-owned programs; SRF388, a Phase 2 program which targets IL-27, and SRF114 which selectively depletes regulatory T cells in the tumor microenvironment via targeting CCR8. In addition, Surface has two partnerships with major pharmaceutical companies: a collaboration with Novartis targeting CD73 (NZV930; Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (GSK4381562, formerly SRF813; Phase 1). Surface’s novel, investigational cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies. For more information, please visit www.surfaceoncology.com.
Contact
Vice President, Investor Relations and Corporate Communications
+1 617 865 3250
syoung@surfaceoncology.com

Source: Surface Oncology, Inc.